High SF3B2 expression is associated with poor prognosis, at least in prostate cancer, bladder cancer, acute myeloid leukemia (AML), lung adenocarcinoma, breast cancer, and head and neck squamous cell carcinoma (HNSCC) [6]. This evidence concerns the gene SF3B2 and prostate cancer.